Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case/non-case malformed study
Authors:
- Laura Saint-LaryLSLaura Saint-Lary
- Anna-Belle BeauABAnna-Belle Beau
- Agnès SommetASAgnès Sommet
- Valériane LeroyVLValériane Leroy
- Maria LoaneMLMaria Loane
- Clara Cavero-CarbonellCCClara Cavero-Carbonell
- Ester GarneEGEster Garne
- Anna Latos BielenskaABAnna Latos Bielenska
- Isabelle MonierIMIsabelle Monier
- Vera NelenVNVera Nelen
Open Access
- 26 February 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (5) , 697-709
Abstract
Purpose: Antiretroviral drugs are recommended during pregnancy to achieve HIV viral suppression and reduce mother-to-child transmission. Congenital anomaly signals were reported after fetal exposure to antiretroviral drugs in several studies warranting further investigation. We aimed to evaluate the risk of congenital anomalies after fetal exposure to antiretroviral drugs using the European congenital anomaly registry data. Methods: A case/non-case study was performed, using the EUROmediCAT central database. All the congenital anomalies, exposed to any antiretroviral drugs, were included from 1995 to 2019. We explored each signal identified from the literature for associations between congenital anomalies and specific antiretroviral exposures. We compared antiretroviral exposure between the signal anomalies (cases) and all other malformed registrations (controls). Reporting odds ratio (ROR) and their 95% confidence intervals were estimated and adjusted for registry and maternal age. Results: Between 1995 and 2019, 173 cases of congenital anomalies were observed after any exposure to antiretroviral drugs. The signal previously identified in the literature between congenital heart defects and exposure to zidovudine was confirmed in the main analysis (aROR 3.66 [1.63–8.23]). Other signals identified in the literature were not confirmed, although two cases of hypospadias and two cases of limb defects were reported after zidovudine and atazanavir exposure, respectively. The signal detection analysis did not reveal any new signal after applying the Bonferroni correction. Conclusions: Our study does not reveal new signals but confirms the previously identified signal between congenital heart defects and fetal exposure to zidovudine. The physio-pathological hypothesis induced by zidovudine exposure should be explored in future studies.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales (12433 B112)
- Université de Toulouse
This publication has 43 references indexed in Scilit:
- In Utero Exposure to Zidovudine and Heart Anomalies in the ANRS French Perinatal Cohort and the Nested PRIMEVA Randomized TrialClinical Infectious Diseases, 2015
- Congenital Anomalies and In Utero Antiretroviral Exposure in Human Immunodeficiency Virus–Exposed Uninfected InfantsJAMA Pediatrics, 2015
- Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11)PLOS Medicine, 2014
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected MothersJAMA, 2011
- Birth Defects Among Children Born to Human Immunodeficiency Virus-Infected WomenThe Pediatric Infectious Disease Journal, 2010
- Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV‐1‐infected womenHIV Medicine, 2008
- Assessing the risk of birth defects associated with antiretroviral exposure during pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapyMitochondrion, 2004
- Periconceptional Exposure to Efavirenz and Neural Tube DefectsArchives of internal medicine (1960), 2002